Medicenna Therapeutics Corp. (MDNA.TO)

2.4200 -0.0200 (-0.82%) As of 09:41AM EDT. Market open.

Medicenna Therapeutics Corp.

2 Bloor Street West
7th Floor
Toronto, ON M4W 3E2
Canada
416- 648-5555
https://www.medicenna.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 16

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Fahar Merchant Ph.D.	Founder, Chairman, President & CEO	454.37k	N/A	1957
Ms. Rosemina Merchant B.Sc., M.E.Sc	Founder & Chief Development Officer	364.46k	N/A	1957
Mr. David Hyman CA, CBV	Chief Financial Officer	N/A	N/A	1973
Dr. Samuel R. Denmeade M.D.	Scientific Advisor	N/A	N/A	N/A

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.

Description

Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops MDNA55, an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.

Corporate Governance

Medicenna Therapeutics Corp.’s ISS Governance QualityScore as of May 1, 2024 is 10. The pillar scores are Audit: 6; Board: 10; Shareholder Rights: 6; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.